Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q5FJ
|
|||
| Former ID |
DNC004798
|
|||
| Drug Name |
8-Phenyl-2-piperidin-1-yl-chromen-4-one
|
|||
| Synonyms |
CHEMBL176064; 8-Phenyl-2-piperidin-1-yl-chromen-4-one; SCHEMBL259239
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H19NO2
|
|||
| Canonical SMILES |
C1CCN(CC1)C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
|
|||
| InChI |
1S/C20H19NO2/c22-18-14-19(21-12-5-2-6-13-21)23-20-16(10-7-11-17(18)20)15-8-3-1-4-9-15/h1,3-4,7-11,14H,2,5-6,12-13H2
|
|||
| InChIKey |
OSJZAQVQDRSBPT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 154447-39-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA-dependent protein kinase catalytic (PRKDC) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Non-homologous end-joining | |||
| Cell cycle | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | |||
| Coregulation of Androgen receptor activity | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| BARD1 signaling events | ||||
| Reactome | Nonhomologous End-Joining (NHEJ) | |||
| WikiPathways | DNA Damage Response | |||
| Non-homologous end joining | ||||
| FAS pathway and Stress induction of HSP regulation | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Prostate Cancer | ||||
| Double-Strand Break Repair | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.